Uncommon Cents Investing LLC bought a new position in Danaher Co. (NYSE:DHR) during the fourth quarter, HoldingsChannel reports. The fund bought 2,500 shares of the conglomerate’s stock, valued at approximately $253,000.
Several other large investors have also added to or reduced their stakes in the company. ETRADE Capital Management LLC grew its position in Danaher by 5.1% during the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares during the last quarter. Roundview Capital LLC grew its position in Danaher by 2.0% during the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares during the last quarter. Honeywell International Inc. grew its position in Danaher by 113.4% during the 3rd quarter. Honeywell International Inc. now owns 640,100 shares of the conglomerate’s stock valued at $54,908,000 after purchasing an additional 340,100 shares during the last quarter. Veritable L.P. grew its position in Danaher by 28.2% during the 2nd quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock valued at $3,417,000 after purchasing an additional 8,912 shares during the last quarter. Finally, Wealthfront Inc. grew its position in Danaher by 10.2% during the 2nd quarter. Wealthfront Inc. now owns 14,574 shares of the conglomerate’s stock valued at $1,230,000 after purchasing an additional 1,348 shares during the last quarter. 77.05% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Angela S. Lalor sold 42,988 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total value of $4,397,242.52. Following the transaction, the senior vice president now owns 82,008 shares in the company, valued at approximately $8,388,598.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the transaction, the chief financial officer now owns 227,805 shares in the company, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. Insiders sold a total of 237,043 shares of company stock worth $24,194,886 in the last quarter. Company insiders own 12.20% of the company’s stock.
Danaher Co. (NYSE DHR) opened at $97.54 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market cap of $67,946.36, a PE ratio of 24.20, a price-to-earnings-growth ratio of 2.05 and a beta of 1.04. Danaher Co. has a one year low of $78.97 and a one year high of $104.82.
Danaher (NYSE:DHR) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The business had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business earned $1.05 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. equities research analysts forecast that Danaher Co. will post 4.37 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend was Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is presently 15.86%.
Several analysts recently commented on the stock. Cowen reissued a “buy” rating and set a $110.00 price objective on shares of Danaher in a research report on Tuesday, January 30th. Credit Suisse Group increased their price objective on shares of Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Royal Bank of Canada reissued a “hold” rating and set a $98.00 price objective on shares of Danaher in a research report on Wednesday, January 31st. Stifel Nicolaus increased their price objective on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley increased their price objective on shares of Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Danaher has a consensus rating of “Buy” and a consensus price target of $100.68.
ILLEGAL ACTIVITY NOTICE: “Uncommon Cents Investing LLC Buys Shares of 2,500 Danaher Co. (DHR)” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/02/19/uncommon-cents-investing-llc-buys-shares-of-2500-danaher-co-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.